NEW YORK (GenomeWeb) - Sysmex today announced that it has partnered with Singapore-based Clearbridge BioMedics to jointly develop a new liquid biopsy system.
The partners will utilize Clearbridge's microfluidics-based rare cell separation technology, with the goal of potentially creating a new product line to complement Sysmex's current suite of hematology analyzers.
A spinout from the National University of Singapore/Singapore-MIT Alliance for Research and Technology, Clearbridge has developed an automated label-free circulating tumor cell enrichment platform, ClearCell FX1, which is based on an inertial focusing microfluidics technology that isolates intact, viable CTCs from patients' blood.
According to Johnson Chen, managing director and founder of Clearbridge, the two companies' liquid biopsy collaboration is the result of a several-years working relationship.
"We both evaluated our technologies and respective intellectual properties, and have concluded there [are] considerable synergies. We are pleased to be in this partnership and bring it to the next level," Chen said in a statement.